World's Best Scientists 2026 revealed!
Jeffrey L. Lennox

Jeffrey L. Lennox

D-Index & Metrics

Microbiology

D-Index
44
Citations
9167
World Ranking
5104
National Ranking
1963

Overview

Jeffrey L. Lennox is affiliated with Emory University in the United States and specializes in multiple areas within medicine, particularly focusing on infectious diseases, epidemiology, virology, neurology, and genetics. Their research primarily addresses topics related to HIV/AIDS drug development and treatment, HIV research and treatment, COVID-19 clinical research studies, pharmacological effects and toxicity studies, long-term effects of COVID-19, sepsis diagnosis and treatment, and genetic associations and epidemiology.

Their recent publications cover notable studies in both infectious diseases and immunology, including:

  • Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial, 2021, The Lancet Respiratory Medicine
  • National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned, 2024, Annals of Internal Medicine
  • Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults, 2021, PLoS Genetics
  • "Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication, 2020, AIDS and Behavior
  • Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy, 2020, Journal of Neuroimmunology

The scientist frequently collaborates with several co-authors, including:

  • Roy M. Gulick
  • Eric S. Daar
  • Jason Baker
  • Jing Zhao
  • Daria J. Hazuda

Jeffrey L. Lennox's work appears in multiple prominent venues with repeated contributions to UNC Libraries, as well as publications in The Lancet Respiratory Medicine, Annals of Internal Medicine, PLoS Genetics, and AIDS and Behavior.

Their research contributions are situated mainly within the medical field, with a strong focus on infectious diseases and related subfields. The range of topics covered demonstrates a focus on both clinical and genetic aspects of infectious diseases, with considerable attention to HIV/AIDS and COVID-19.

Best Publications

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

    Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  • Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

    Samir K. Gupta;Joseph A. Eustace;Jonathan A. Winston;Ivy I. Boydstun

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial

    Jeffrey L. Lennox;Raphael J. Landovitz;Heather J. Ribaudo;Ighovwerha Ofotokun

  • Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

    Jürgen K Rockstroh;Edwin DeJesus;Jeffrey L Lennox;Yazdan Yazdanpanah

  • Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

    Roy T. Steigbigel;David A. Cooper;Hedy Teppler;Joseph J. Eron

  • Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Gregory M. Lucas;Michael J. Ross;Peter G. Stock;Michael G. Shlipak

  • Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

    Jeffrey L. Lennox;Edwin DeJesus;Daniel S. Berger;Adriano Lazzarin

  • A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis

    Philip J Peters;Taylor Harrison;Jeffrey L Lennox

  • Correlation of Human Immunodeficiency Virus Type 1 RNA Levels in Blood and the Female Genital Tract

    Clyde E. Hart;Jeffrey L. Lennox;Melody Pratt-Palmore;Thomas C. Wright

  • HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.

    Christopher D. Pilcher;Diane C. Shugars;Susan A. Fiscus;William C. Miller

  • Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

    Jürgen K. Rockstroh;Jeffrey L. Lennox;Edwin Dejesus;Michael S. Saag

  • Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.

    Daniel R. Feikin;Cheryl M. Elie;Matthew B. Goetz;Jeffrey L. Lennox

  • Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines

    Sunil Kannanganat;Bill G. Kapogiannis;Bill G. Kapogiannis;Chris Ibegbu;Lakshmi Chennareddi

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

    Zeruesenay Desta;Roseann S. Gammal;Roseann S. Gammal;Li Gong;Michelle Whirl-Carrillo

  • Healthy HIV-1-Infected Individuals on Highly Active Antiretroviral Therapy Harbor HIV-1 in Their Alveolar Macrophages

    Sushma K. Cribbs;Jeffrey Lennox;Angela M. Caliendo;Lou Ann Brown

  • Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

    Joseph J. Eron;David A. Cooper;Roy T. Steigbigel;Bonaventura Clotet

  • Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients

    James L. Cole;Ulla M. Marzec;Clifford J. Gunthel;Simon Karpatkin

  • Impaired Hepatitis C Virus (HCV)-Specific Effector CD8+ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection

    Henry Radziewicz;Chris C. Ibegbu;Huiming Hon;Melissa K. Osborn

  • Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.

    Kehmia Titanji;Aswani Vunnava;Anandi N. Sheth;Cecile Delille

  • Infrequent Diagnosis of Primary Human Immunodeficiency Virus Infection: Missed Opportunities in Acute Care Settings

    Amy C. Weintrob;Julieta Giner;Prema Menezes;Ericka Patrick

  • Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.

    C. Robert Horsburgh;Jill Gettings;Lorraine N. Alexander;Jeffrey L. Lennox

Frequent Co-Authors

David W. Haas
David W. Haas Vanderbilt University Medical Center
Kirk A. Easley
Kirk A. Easley Emory University
Judith S. Currier
Judith S. Currier University of California, Los Angeles
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
Carlos del Rio
Carlos del Rio Emory University
Jürgen K. Rockstroh
Jürgen K. Rockstroh University Hospital Bonn
M. Neale Weitzmann
M. Neale Weitzmann Emory University
Randi Y. Leavitt
Randi Y. Leavitt MSD (United States)
Thomas C. Wright
Thomas C. Wright Columbia University
Matthew Bidwell Goetz
Matthew Bidwell Goetz University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in exploring alternative or complementary fields to Microbiology, online degrees in healthcare and health information management offer promising career opportunities. Programs recognized as the best online health information management degree cahiim accredited ensure quality education that meets industry standards, preparing graduates for roles in managing patient data and healthcare systems.

If you're looking to quickly enter the healthcare administration sector, accelerated options like medical billing and coding certificate online accelerated programs can provide certification in a matter of months, opening doors to essential, high-demand positions.

Moreover, for those aiming higher in the healthcare field, understanding online healthcare degrees that pay well can guide decision-making toward degrees that yield strong financial returns and stable job prospects.

Finally, public health is a growing sector where many microbiology graduates find meaningful roles. The availability of easy admission online mph programs allows motivated individuals to continue their education without the hassle of stringent entry requirements, making it an accessible path to advance your career in managing health on a larger scale.

Best Scientists Citing Jeffrey L. Lennox

Trending Scientists

Recently Published Articles